Clinical Scorecard: Cellares and City of Hope to Automate Manufacturing of Solid Tumor CAR T Cell Therapy
At a Glance
| Category | Detail |
|---|---|
| Condition | Glioblastoma multiforme |
| Key Mechanisms | Gene-modified CAR T cell therapy targeting IL13RA2-EGFR |
| Target Population | Patients with glioblastoma, approximately 300,000 new diagnoses annually |
| Care Setting | Cancer research and treatment organizations |
Key Highlights
- Collaboration to evaluate automated manufacturing of CAR T cell therapy
- City of Hope's expertise in CAR T for glioblastoma
- Use of Cell Shuttle™ and Cell Q™ for high-throughput manufacturing
- Focus on addressing challenges of immunosuppressive tumor microenvironment
- Goal to standardize processes for effective clinical translation
Guideline-Based Recommendations
Diagnosis
- Evaluate glioblastoma through imaging and histopathological assessment
Management
- Utilize gene-modified CAR T cell therapy targeting IL13RA2-EGFR
Monitoring & Follow-up
- Assess treatment response and monitor for adverse effects post-therapy
Risks
- Consider risks associated with immunosuppressive tumor microenvironment and antigen heterogeneity
Patient & Prescribing Data
Patients diagnosed with glioblastoma multiforme
Automated manufacturing aims to enhance scalability and reproducibility of CAR T therapies
Clinical Best Practices
- Incorporate automation in early development stages
- Standardize manufacturing processes and analytics
- Focus on reproducibility to lower failure rates
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
